Bugge, T. H., Antalis, T. M. & Wu, Q. Type II transmembrane serine proteases. J. Biol. Chem. 284, 23177–23181 (2009).
Forni, D., Sironi, M. & Cagliani, R. Evolutionary history of type II transmembrane serine proteases involved in viral priming. Hum. Genet. 141, 1705–1722 (2022).
Paoloni-Giacobino, A., Chen, H., Peitsch, M. C., Rossier, C. & Antonarakis, S. E. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 44, 309–320 (1997).
Wettstein, L., Kirchhoff, F. & Münch, J. The transmembrane protease TMPRSS2 as a therapeutic target for COVID-19 treatment. Int. J. Mol. Sci. 23, 1351 (2022).
Böttcher, E. et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 80, 9896–9898 (2006).
Limburg, H. et al. TMPRSS2 is the major activating protease of influenza A virus in primary human airway cells and influenza B virus in human type II pneumocytes. J. Virol. 93, 10–1128 (2019).
Chaipan, C. et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 83, 3200–3211 (2009).
Abe, M. et al. TMPRSS2 is an activating protease for respiratory parainfluenza viruses. J. Virol. 87, 11930 (2013).
Shirogane, Y. et al. Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J. Virol. 82, 8942–8946 (2008).
Shirato, K., Kawase, M. & Matsuyama, S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 87, 12552 (2013).
Glowacka, I. et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 85, 4122–4134 (2011).
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271 (2020).
Saunders, N. et al. TMPRSS2 is a functional receptor for human coronavirus HKU1. Nature 624, 207–214 (2023).
Xia, L., Zhang, Y. & Zhou, Q. Structural basis for the recognition of HCoV-HKU1 by human TMPRSS2. Cell Res. 2024, 1–4. https://doi.org/10.1038/s41422-024-00958-9 (2024).
McCallum, M. et al. Human coronavirus HKU1 recognition of the TMPRSS2 host receptor. bioRxiv Prepr. Serv. Biol. https://doi.org/10.1101/2024.01.09.574565 (2024).
Wang, H. et al. TMPRSS2 and glycan receptors synergistically facilitate coronavirus entry. Cell 187(16), 4261–4271 (2024).
Fernández, I. et al. Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus. Cell 187(16), 4246–4260 (2024).
Iwata-Yoshikawa, N. et al. Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways. Nat. Commun. 13, 1–11 (2022).
Liu, J. et al. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov. 7, 1–4 (2021).
Chu, H. et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study. Lancet Microbe 1, e14–e23 (2020).
Conceicao, C. et al. The SARS-CoV-2 spike protein has a broad tropism for mammalian ACE2 proteins. PLOS Biol. 18, e3001016 (2020).
Koch, J. et al. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. EMBO J. 40, e107821 (2021).
Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3–20 (2021).
Takeda, M. Proteolytic activation of SARS-CoV-2 spike protein. Microbiol. Immunol. 66, 15–23 (2022).
Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161–1179 (2022).
Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706–714 (2022).
Hu, B. et al. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. Emerg. Microbes Infect. 11, 2275–2287 (2022).
Shi, G. et al. Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue. Nat. Commun. 15, 889 (2024).
Metzdorf, K. et al. TMPRSS2 is essential for SARS-CoV-2 beta and Omicron infection. Viruses 15, 271 (2023).
Huang, I. C. et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLOS Pathog. 7, e1001258 (2011).
Bertram, S. et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J. Virol. 87, 6150–6160 (2013).
Zheng, M. et al. Bat SARS-Like WIV1 coronavirus uses the ACE2 of multiple animal species as receptor and evades IFITM3 restriction via TMPRSS2 activation of membrane fusion. Emerg. Microbes Infect. 9, 1567 (2020).
Peacock, T. P. et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 6, 899–909 (2021).
Wrensch, F., Winkler, M. & Pöhlmann, S. IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: Evidence for cholesterol-independent mechanisms. Viruses 6, 3683–3698 (2014).
Winstone, H. et al. The polybasic cleavage site in SARS-CoV-2 spike modulates viral sensitivity to type I interferon and IFITM2. J. Virol. 95, 10–1128 (2021).
Xu, F. et al. IFITM3 inhibits SARS-CoV-2 infection and is associated with COVID-19 susceptibility. Viruses 14, 2553 (2022).
Shi, G. et al. Opposing activities of IFITM proteins in SARS-CoV-2 infection. EMBO J. 40, e106501 (2021).
Huang, J. et al. SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Cell Stem Cell 27, 962-973.e7 (2020).
Xie, Q. et al. Endogenous IFITMs boost SARS-coronavirus 1 and 2 replication whereas overexpression inhibits infection by relocalizing ACE2. iScience 26, 106395 (2023).
Prelli Bozzo, C. et al. IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. Nat. Commun. 12, 1–13 (2021).
Nchioua, R. et al. SARS-CoV-2 variants of concern hijack IFITM2 for efficient replication in human lung cells. J. Virol. 96, e00594 (2022).
Afar, D. E. H. et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 61, 1686–1692 (2001).
Vaarala, M. H. et al. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J. Pathol. https://doi.org/10.1002/1096-9896(2000)9999:9999 (2000).
Dong, M. et al. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed. Pharmacother. 131, 110678 (2020).
Singh, M., Bansal, V. & Feschotte, C. A single-cell RNA expression map of human coronavirus entry factors. Cell Rep. 32, 108175 (2020).
Muus, C. et al. Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. Nat. Med. 27, 546–559 (2021).
Sungnak, W. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. https://doi.org/10.1038/s41591-020-0868-6 (2020).
Burgueno, J. F. et al. Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD. Inflamm. Bowel Dis. 26, 797 (2020).
Lehmann, M. et al. Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cells. Mucosal Immunol. 14, 1381–1392 (2021).
Lamers, M. M. et al. SARS-CoV-2 productively infects human gut enterocytes. Science 369, 50–54 (2020).
Zhou, J. et al. Infection of bat and human intestinal organoids by SARS-CoV-2. Nat. Med. 26, 1077–1083 (2020).
Wu, X. et al. Intestinal damage in COVID-19: SARS-CoV-2 infection and intestinal thrombosis. Front. Microbiol. 13, 860931 (2022).
Guimarães Sousa, S. et al. SARS-CoV-2 infection causes intestinal cell damage: Role of interferon’s imbalance. Cytokine 152, 155826 (2022).
Cheung, K. S. et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in Fecal samples from a Hong Kong cohort: Systematic review and meta-analysis. Gastroenterology 159, 81–95 (2020).
Mao, R. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 667–678 (2020).
Lin, L. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69, 997–1001 (2020).
Lin, B. et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180–4184 (1999).
Lucas, J. M. et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 4, 1310 (2014).
Jacquinet, E. et al. Cloning and characterization of the cDNA and gene for human epitheliasin. Eur. J. Biochem. 268, 2687–2699 (2001).
Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
Wang, J., Cai, Y., Ren, C. & Ittmann, M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 66, 8347–8351 (2006).
Qiao, Y. et al. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. Proc. Natl. Acad. Sci. USA 118, e2021450118 (2020).
Deng, Q., ur Rasool, R., Russell, R. M., Natesan, R. & Asangani, I. A. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. iScience 24(3), 102254. https://doi.org/10.1016/j.isci.2021.102254 (2021).
Chen, Y. et al. A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry. Nat. Commun. 12, 1–15 (2021).
Pommerenke, C. et al. Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies. PLoS ONE 16, e0255622 (2021).
Partridge, L. J. et al. Ace2-independent interaction of sars-cov-2 spike protein with human epithelial cells is inhibited by unfractionated heparin. Cells 10, 1419 (2021).
Pandamooz, S. et al. Experimental models of SARS-CoV-2 infection: Possible platforms to study COVID-19 pathogenesis and potential treatments. Ann. Rev. Pharmacol. Toxicol. 62, 25–53 (2022).
Pires De Souza, G. A. et al. Choosing a cellular model to study SARS-CoV-2. Front. Cell. Infect. Microbiol. 12, 1003608 (2022).
Crozier, T. W. M. et al. Quantitative proteomic analysis of SARS-CoV-2 infection of primary human airway ciliated cells and lung epithelial cells demonstrates the effectiveness of SARS-CoV-2 innate immune evasion. Wellcome Open Res. 7, 224 (2022).
Ye, C. et al. Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. Proc. Natl. Acad. Sci. USA 118, e2111593118 (2021).
Chiem, K. et al. Generation and characterization of recombinant SARS-CoV-2 expressing reporter genes. J. Virol. https://doi.org/10.1128/JVI.02209-20 (2021).
Chan, J. F. W. et al. Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. Cell Rep. Med. 3, 100743 (2022).
Tzelepis, K. et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 17, 1193–1205 (2016).
Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2, 423–427 (2000).
Tanimoto, K. Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19, 4298–4309 (2000).
Champion, A. et al. MORC3 represses the HCMV major immediate early promoter in myeloid cells in the absence of PML nuclear bodies. J. Med. Virol. 95, e29227 (2023).
Jeronimo, C. & Robert, F. The histone chaperone FACT: A guardian of chromatin structure integrity. Transcription 13, 16–38 (2022).
Mason, P. B. & Struhl, K. The FACT complex travels with elongating RNA polymerase II and is important for the fidelity of transcriptional initiation in vivo. Mol. Cell. Biol. 23, 8323 (2003).
Jamin, A. & Wiebe, M. S. Barrier to autointegration factor (BANF1): Interwoven roles in nuclear structure, genome integrity, innate immunity, stress responses and progeria. Curr. Opin. Cell Biol. 34, 61 (2015).
Schoenfeld, A. R., Davidowitz, E. J. & Burk, R. D. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc. Natl. Acad. Sci. USA 97, 8507–8512 (2000).
Mykytyn, A. Z. et al. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models. J. Virol. 97, e00851 (2023).
Pastorio, C. et al. Impact of mutations defining SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 on Spike function and neutralization. iScience 26, 108299 (2023).
Zhang, L. et al. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell 187, 596–608 (2024).
Tang, W. F., Tran, A. T., Wang, L. Y. & Horng, J. T. SARS-CoV-2 pandemics: An update of CRISPR in diagnosis and host–virus interaction studies. Biomed. J. 46, 100587 (2023).
Bailey, A. L. & Diamond, M. S. A Crisp(r) new perspective on SARS-CoV-2 biology. Cell 184, 15–17 (2021).
Biering, S. B. et al. Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection. Nat. Genet. 54, 1078–1089 (2022).
Rebendenne, A. et al. Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs. Nat. Genet. 54, 1090–1102 (2022).
Daniloski, Z. et al. Identification of required host factors for SARS-CoV-2 infection in human cells. Cell 184, 92-105.e16 (2021).
Wang, R. et al. Genetic screens identify host factors for SARS-CoV-2 and common cold coronaviruses. Cell 184, 106-119.e14 (2021).
Zhu, Y. et al. A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. Nat. Commun. 12, 1–11 (2021).
Wei, J. et al. Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell 184, 76-91.e13 (2021).
Chan, K. et al. Survival-based CRISPR genetic screens across a panel of permissive cell lines identify common and cell-specific SARS-CoV-2 host factors. Heliyon 9, e12744 (2023).
Hou, J. et al. Integrated multi-omics analyses identify anti-viral host factors and pathways controlling SARS-CoV-2 infection. Nat. Commun. 15, 1–14 (2024).
Israeli, M. et al. Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2. Nat. Commun. 13, 1–16 (2022).
Sherman, E. J. et al. Identification of cell type specific ACE2 modifiers by CRISPR screening. PLOS Pathog. 18, e1010377 (2022).
Cavadas, M. A. S., Cheong, A. & Taylor, C. T. The regulation of transcriptional repression in hypoxia. Exp. Cell Res. 356, 173–181 (2017).
Choudhry, H. & Harris, A. L. Advances in hypoxia-inducible factor biology. Cell Metab. 27, 281–298 (2018).
Batie, M., del Peso, L. & Rocha, S. Hypoxia and chromatin: A focus on transcriptional repression mechanisms. Biomedicines 6, 47 (2018).
Cavadas, M. A. S. et al. REST is a hypoxia-responsive transcriptional repressor. Sci. Rep. 6, 1–13 (2016).
Kulshreshtha, R. et al. A microRNA signature of hypoxia. Mol. Cell. Biol. 27, 1859–1867 (2007).
Dengler, V. L., Galbraith, M. D. & Espinosa, J. M. Transcriptional regulation by hypoxia inducible factors. Crit. Rev. Biochem. Mol. Biol. 49, 1 (2014).
Zhang, R. et al. MiRNA let-7b promotes the development of hypoxic pulmonary hypertension by targeting ACE2. Am. J. Physiol. Lung Cell. Mol. Physiol. 316, L547–L557 (2019).
Wing, P. A. C. et al. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. Cell Rep. 35, 109020 (2021).
Codo, A. C. et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis. Cell Metab. 32, 437-446.e5 (2020).
Sturrock, A., Zimmerman, E., Helms, M., Liou, T. G. & Paine, R. Hypoxia induces expression of angiotensin-converting enzyme II in alveolar epithelial cells: Implications for the pathogenesis of acute lung injury in COVID-19. Physiol. Rep. 9, e14854 (2021).
Imperio, G. E. et al. Hypoxia alters the expression of ACE2 and TMPRSS2 SARS-CoV-2 cell entry mediators in hCMEC/D3 brain endothelial cells. Microvasc. Res. 138, 104232 (2021).
Shilts, J. et al. LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein. PLOS Biol. 21, e3001959 (2023).
Burr, M. L. et al. CMTM6 maintains the expression of PD-L1 and regulates anti-Tumour immunity. Nature 549, 101–105 (2017).
Menzies, S. A. et al. The sterol-responsive RNF145 E3 ubiquitin ligase mediates the degradation of HMG-CoA reductase together with gp78 and hrd1. Elife 7, e40009 (2018).
Morgens, D. W. et al. Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat. Commun. 8, 15178 (2017).
Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80–84 (2014).
Michlits, G. et al. Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles. Nat. Methods 17, 708–716 (2020).
Ortmann, B. M. et al. The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes. Nat. Genet. 53, 1022–1035 (2021).
Lambert, S. A. et al. The human transcription factors. Cell 172, 650–665 (2018).
Medvedeva, Y. A. et al. EpiFactors: A comprehensive database of human epigenetic factors and complexes. Database https://doi.org/10.1093/database/bav067 (2015).
Williams, R. T. et al. ZBTB1 regulates asparagine synthesis and leukemia cell response to L-asparaginase. Cell Metab. 31, 852-861.e6 (2020).
Gu, Z. et al. Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia. Nat. Genet. 53, 672–682 (2021).
Hart, T. et al. Evaluation and design of genome-wide CRISPR/SpCas9 knockout screens. G3 7, 2719–2727 (2017).
Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184–191 (2016).
DeWeirdt, P. C. et al. Genetic screens in isogenic mammalian cell lines without single cell cloning. Nat. Commun. 11, 1–15 (2020).
Mölder, F. et al. Sustainable data analysis with Snakemake. F1000Research 10, 33 (2021).
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011).
Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 15, 554 (2014).
Hartenian, E., Gilbertson, S., Federspiel, J. D., Cristea, I. M. & Glaunsinger, B. A. RNA decay during gammaherpesvirus infection reduces RNA polymerase II occupancy of host promoters but spares viral promoters. PLOS Pathog. 16, e1008269 (2020).
Brevini, T. et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nat. 615, 134–142 (2022).
Grodzki, M. et al. Genome-scale CRISPR screens identify host factors that promote human coronavirus infection. Genome Med. 14, 1–18 (2022).
Pleguezuelos-Manzano, C. et al. Establishment and culture of human intestinal organoids derived from adult stem cells. Curr. Protoc. Immunol. 130, e106 (2020).
Tysoe, O. C. et al. Isolation and propagation of primary human cholangiocyte organoids for the generation of bioengineered biliary tissue. Nat. Protoc. 14, 1884–1925 (2019).
Sampaziotis, F. et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science 371, 839–846 (2021).
